Cerecin and IMCB have signed a memorandum of understanding to collaborate in the areas of neurometabolism, neurodegeneration, metabolic regulators and brain health and function.
SINGAPORE And DENVER, December 1, 2023 /PRNewswire/ — Cerecin Inc., a clinical-stage biotechnology company at the forefront of developing innovative neurotherapeutics, is pleased to announce the establishment of a Memorandum of Understanding (MOU) with the Institute of Molecular Biology and Cellular (IMCB) from A*STAR. . This collaboration aims to accelerate research and treatment initiatives for neurological disorders and diseases to improve overall health and brain function.
Worldwide, there are approximately two billion cases of neurological and mental illnesses. Unlike other therapeutic areas, 80% of these patients are not treated at all or have been insufficiently treated by current medications used to treat their pathology. This makes brain health one of the medical areas with the greatest unmet need. In Singapore More than one in four people alone will suffer from a neurological disease in their lifetime.
It is becoming increasingly clear that neurometabolic dysfunction underlies many neurological and neurodegenerative diseases, and that metabolic health and brain health are closely linked. Thus, in their collaboration, A*STAR’s IMCB will combine preclinical modeling tools with multi-omics approaches to analyze biological samples of neurological diseases (such as Alzheimer’s disease) from Cerecin’s clinical cohorts. The objective is to understand the fundamental causes of these neurological diseases, in particular their metabolic origins, to identify new therapeutic targets and disease indicators, and to develop innovative therapeutic approaches.
“We are very excited to embark on this collaborative journey with A*STAR’s IMCB, initially focused on collaboration with its Neurometabolism division,” said Dr. Charles Stacey, CEO and President of Cerecin. “This partnership represents another step in our commitment to advancing neurometabolism and underscores our commitment to providing cutting-edge solutions. Singapore has a rapidly aging population. With age being the primary risk factor for many neurodegenerative diseases, we are proud to form one of the first public-private collaborations in brain health.
Dr Su Xinyi, Acting Executive Director of A*STAR IMCB, said: “Public-private partnerships are key tools for translating science into impact. IMCB’s expertise in neurometabolism, cell biology, transformational biotherapeutics and diagnostics, combined with Cerecin’s expertise, will help pave the way for the future. pave the way for innovative developments in neurotherapeutics and contribute to better health outcomes for Singapore and beyond.”
About Cerecin:
Cerecin is a clinical-stage biotechnology company focused on the development of drugs targeting the metabolic bases of central nervous system diseases. Cerecin is backed by two multinational partners, Nestlé SA (NSRGY) and Wilmar International Limited (SGX: F34), as well as a syndicate of leading institutional investors. By bringing together the deep expertise of its management team, Cerecin becomes a global leader in bioenergetics and neurometabolism.
Forward-looking statements:
This press release contains “forward-looking statements” under applicable securities laws that are based on Cerecin’s current expectations and beliefs. Such statements may be accompanied by words such as “aim”, “anticipate”, “believe”, “could”, “estimate”, “expect”, “forecast”, “intend”, “may” , “plan”, “potential”, “possible”, “will” and other words and terms of similar meaning. All statements, except statements of historical fact, are statements that could be deemed forward-looking statements, including, but not limited to: (i) sources and availability of financing and investments third parties and the projected financial performance of the Company; (ii) the expected development of the Company’s activities, projects, drug development programs and joint ventures; (iii) execution of the Company’s vision and growth strategy, including with respect to future growth; and (iv) new developments regarding the Company’s projects that are currently underway, under development or otherwise under consideration. The development and commercialization of drugs involves a high degree of risk, and only a small number of research and development programs result in the commercialization of a product. Results from early-stage clinical trials may not be representative of the full results or results from later-stage or larger-scale clinical trials and do not guarantee regulatory approval. Forward-looking statements are not guarantees of future performance and undue reliance should not be placed on them. These forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from projections of future performance or any results that may be expressed or implied by such statements. prospective. Although the forward-looking statements contained in this press release are based on what Cerecin’s management believes to be reasonable assumptions, there can be no assurance or guarantee that the forward-looking statements will prove to be accurate, as actual results and Future events could differ materially from these. those anticipated in such statements. Cerecin undertakes no obligation to update any forward-looking statements if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
For more information, visit www.cerecin.com.
For more information, please contact: pr@cerecin.com
© 2023 Cerecin AC-23-976
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/cerecin-forges-strategic-partnership-with-astars-institute-of-molecular-and-cell-biology-imcb-in-singapore-to-advance- rd-in-neurological-disorders-302002723.html
SOURCE Cérécin